Journal of Cancer Genetics and Biomarkers
Reading the cancer genome — from variant to biomarker to clinical decision.
JCGB publishes peer-reviewed research on the molecular genetics of cancer and the biomarkers that turn it into precision oncology — open access under CC BY, with permanent Crossref DOIs and an international editorial board. Publishing since 2014.
Where molecular mechanism meets biomarker translation
JCGB publishes work that connects the molecular biology of cancer to biomarkers with translational value — mechanism, discovery, and validation in one place.
Molecular tumorigenesis
Oncogenic pathway dysregulation, tumour-suppressor loss, genomic instability, and the DNA-damage response.
Biomarker discovery & validation
Genomic, transcriptomic, and proteomic signatures for stratification, prognosis, and therapy selection.
ctDNA, CTCs & MRD
Circulating tumour DNA, tumour cells, exosomes, and minimal-residual-disease monitoring.
Tumour & clonal dynamics
Clonal architecture, mutational signatures, metastasis, and therapy-induced evolution.
Targets & pharmacogenomics
Druggable-target identification, acquired resistance, synthetic lethality, and response genomics.
Hereditary predisposition
Inherited cancer syndromes, germline variant pathogenicity, and familial-cancer biomarkers.
Cancer epigenetics
DNA methylation, histone and chromatin remodelling, and non-coding-RNA regulation.
Tumour microenvironment
Immune, stromal, and metabolic interactions shaping progression and treatment response.
Functional & computational genomics
CRISPR screens, organoid and PDX models, single-cell and spatial multi-omics for precision oncology.
Built for cancer-genetics research, and for the people who read it
Genuinely open
Published under CC BY with copyright retained by you, so your work reaches the widest readership without paywalls.
Rigorously reviewed
Single-blind (double-blind on request), managed by an editorial board of working molecular-oncology scientists.
Read where it matters
A global audience of cancer geneticists, oncologists, and pathologists working across precision oncology.
Permanent & citable
Every article receives a permanent Crossref DOI under ISSN 2572-3030 — linkable and citable for good.
An international editorial board
Every submission is handled by practising cancer researchers and pathologists at leading institutions — the standard your work is measured against.
Selected recent research
A sample of work published in JCGB — each with a permanent DOI you can follow now.
High-Throughput Complex-Disease Modeling for Ethical Drug Discovery: Clinical Relevance of a NAM Platform for Cancer Biomarker Development
Dillier E, Sousa R, Kluser T, et al.
Dynamic MicroRNA Expression in Plasma of Melanoma Patients Correlates with Progression, PD-L1 Status, and Overall Survival
Degenhardt S, Bender M, Chen I-P, et al.
Targeting the Mutational Landscape of TP53 in Patients Diagnosed with Oral Cancer Living in Senegal
Sarr PD, Touré S, El Fahime E, et al.
Long Non-Coding RNAs Emerging as Potential Epigenetic Biomarkers for Tobacco/Alcohol-Induced Head and Neck Cancer
Gupta S, Kumar P, Maini J, Bharadwaj M
Priced clearly, permanently identified
Article processing charge
A single charge applies to every accepted article, whatever its type — there is no separate submission or review fee.
- Peer-review management and editorial handling
- Professional production, typesetting, and hosting
- A permanent Crossref DOI and indexing metadata
- Open-access publication under CC BY
Waivers of up to 25% are available by exception.
Full charge & waiver details →Identifiers & discovery
What JCGB states plainly, and can verify:
- Every article carries a permanent Crossref DOI (prefix 10.14302/issn.2572-3030)
- Registered under ISSN 2572-3030 in the global ISSN Portal
- Content is discoverable through search engines and the open web
- Free to read, share, and self-archive under CC BY
- Participating in the Portico digital-preservation program